Olmesartan-associated enteropathy: attention to an emerging iatrogenic phenomenon
DOI:
https://doi.org/10.23938/ASSN.0021Keywords:
Olmesartan. Adverse effects. Celiac disease/chemically induced. Malabsorption syndrome/chemically induced.Abstract
ABSTRACT
Olmesartan is an angiotensin II type 1 receptor blocker commonly used in the treatment of hypertension. Several cases of sprue-like enteropathy associated with the use of this drug have been described which, even with important signs and limitations for the patient, present a full recovery after discontinuing the use of olmesartan.
The case of a 64 year-old patient is presented, diagnosed with hypertension, under treatment with olmesartan-amlodipine, with chronic diarrhoea and villous atrophy on intestinal biopsies without diagnostic criteria for celiac disease and with complete remission after suspending discontinuing the use of olmesartan.
Based on the clinical features presented by the case reported, the clinical and anatomopathological findings are described as well as the evolution of drug-induced enteropathy.
Downloads
References
RUBIO-TAPIA A, HERMAN ML, LUDVIGSSON JF, KELLY DG, MANGAN TF, WU TT et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87: 732-738.
FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm. Published 2013.
MONTALTO M, RICCI R, GASBARRINI A, CAMMAROTA G. Alimentary Pharmacology and Therapeutics Systematic review : sprue-like enteropathy associated with olmesartan. 2014; 40: 16-23.
BURBURE N, LEBWOHL B, ARGUELLES-GRANDE C, GREEN PHR, BHAGAT G, LAGANA S. Olmesartan-associated sprue-like enteropathy: A systematic review with emphasis on histopathology. Hum Pathol 2016; 50: 127-134.
TÉLLEZ VILLAJOS L, CRESPO PÉREZ L, CANO RUIZ A. Atrofia vellositaria sin enfermedad celíaca: ¿un nuevo síndrome o más confusión? Med Clin (Barc) 2015; 144: 121-125.
MENNE J, HALLER H. Olmesartan and intestinal adverse effects in the ROADMAP study. Mayo Clin Proc 2012; 87 :1230-1231.
TRAN TH, LI H. Olmesartan and drug-induced enteropathy. P T a peer-reviewed. J Formul Manag 2014; 39: 47-50.
MARIETTA E .V, CARTEE A, RISHI A, MURRAY JA. Drug-induced enteropathy. Dig Dis 2015; 33: 215-220.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
